Core Viewpoint - The company *ST Dongyi has entered a restructuring plan approved by the Beijing First Intermediate Court, which aims to improve its financial health and sustainability, impacting its financial data for 2025 [3][4]. Group 1: Restructuring Process - On December 21, the company received a civil ruling from the Beijing First Intermediate Court approving its restructuring plan and terminating the restructuring process [3]. - The restructuring plan was approved by the company's investor meeting on December 19, and the first creditors' meeting on December 21 also approved the plan [4]. - The company will execute the restructuring plan while a designated management team will supervise its implementation, which is expected to improve the company's asset-liability structure [4]. Group 2: Risks and Challenges - The company has highlighted multiple risks, including the potential for bankruptcy if the restructuring plan is not executed, and the risk of stock delisting due to negative net assets and uncertain operating capabilities [5]. - Even if the restructuring is completed successfully, the company may still face delisting risks if it fails to meet the Shenzhen Stock Exchange's requirements [5]. Group 3: Capital Increase and Investment - The restructuring plan includes a capital increase where existing shareholders will not receive new shares, with a total of 5.32 billion shares to be issued, raising the total share count to 9.51 billion [5]. - The restructuring investors, including Beijing Huazhu Technology Co., Ltd. and Yunnan International Trust Co., Ltd., will provide an investment of 1.412 billion yuan [6]. - Huazhu Technology, controlled by Zhang Jianhua, will not transfer its shares for 36 months, while financial investors will not transfer theirs for 12 months [6]. Group 4: Business Strategy Post-Reconstruction - After the restructuring, the company will focus on its core home decoration business and upgrade its digital home decoration services [7]. - The restructuring investors will leverage their resources in the computing power industry to assist the company in expanding its integrated service and operation services for computing power centers [7]. - Zhang Jianhua will remain the actual controller of the company post-restructuring, with plans to inject equity from a computing center into the company to facilitate business transformation [7]. Group 5: Market Performance - Since the announcement of the restructuring investor selection on September 26, the company's stock has experienced significant volatility, achieving 24 trading limits in 29 days, with a peak price of 18.6 yuan on November 20 before a subsequent decline [7].

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、将进入重整执行阶段 具体来说，公司及其子公司将部分内部承包项目按照自营项目进行核算，导致少记成本、虚增利润。 2017年至2021年期间，分别虚增利润1833.44万元至4398.64万元不等。 这些虚假的财务数据不仅体现在年报中，也被用于2019年和2021年公开发行的可转换公司债券募集说明 书以及2020年的股份发行文件中。 公司能否彻底告别过去，在全新的股权结构和管理层带领下走上合规经营、健康发展的道路，仍需时间 检验。高票通过的重整计划草案显示了债权人对公司重生的期待。而因虚假陈述受损的投资者，则通过 法律途径寻求赔偿。 （本文由上海沪紫律师事务所刘鹏律师供稿，不代表新浪财经的观点。刘鹏律师，专注证券维权19年， 自2006年执业以来，成功为中青宝、国华网安、劲嘉股份（维权）等 300 余家上市公司的中小投资者成 功维权，案件在办数量超过 14000 起，胜诉率达 99.2%。作为业内 ...

智通财经记者 | 李香才 12月17日，上海金融法院开庭审理了备受资本市场关注的"平安诉华夏幸福案"。 柏文喜进一步分析说："案件一旦进入实体审理，华夏幸福将直面仲裁协议效力之争；若被认定无效，平安即可通过法院诉讼快速查封资产、公开裁判， 对华夏幸福声誉和重整计划造成二次冲击。先用程序异议把节奏慢下来，可为其争取谈判时间或重整窗口 。" 时间回溯到2018年，平安人寿受让华夏幸福19.7%股份，本次受让后平安人寿及其一致行动人平安资管受托管理资金共持有华夏幸福19.88%股份。对于此 次收购，平安人寿当时表示，主要基于看好华夏幸福未来长期发展潜力，以获得稳定的股息分红，分享长期价值投资收益。 彼时，华夏控股向平安人寿、平安资管承诺，华夏幸福2018、2019、2020年度归属于上市公司股东的净利润分别不低于114.15亿元、144.88亿元、180.01 亿元。如上市公司前述任一会计年度实际净利润小于承诺净利润的95%，则华夏控股应予补偿。 华夏幸福2018年和2019年达成业绩承诺，不过，2020年则相差甚远，因此触发补偿条款。 中国平安人寿保险股份有限公司、 平安资产管理有限责任公司作为原告，华夏幸福基业 ...

Company Control Change - *ST Ningke has experienced a significant stock price increase, achieving five consecutive trading limits. The company is currently in the execution phase of its restructuring plan [1][3] - The company announced that its controlling shareholder and actual controller will change, with Liu Xirong becoming the new actual controller [1][3] - On December 16, the company disclosed that 882 million shares, accounting for 54.64% of the total share capital, were transferred from the management's securities account to the designated securities account of the restructuring investor [1][3] Financial Misrepresentation - In 2022, the company inflated its operating revenue by 76.5941 million yuan and its total profit by 77.222 million yuan, representing 11.25% and 46.59% of the respective figures for that period [1][3] - The company failed to disclose significant events in a timely manner, particularly regarding major debts and the suspension of key business operations of its subsidiaries [1][3] Investor Compensation - The successful restructuring of *ST Ningke is expected to benefit investor compensation efforts. The restructuring plan is set to be executed until December 31, 2025 [2][4] - Investors who meet specific criteria can actively participate in compensation registration to recover losses incurred due to the company's financial misrepresentation [2][4] - Legal representation by experienced lawyers, such as Liu Peng, is emphasized as crucial for maximizing investor rights and compensation outcomes [2][4]

*ST中装公告称，2025年12月18日，公司收到深圳中院送达的《民事裁定书》，其裁定批准公司重整计 划，并终止重整程序。此前，12月16日，公司第二次债权人会议和出资人组会议已分别表决通过重整计 划草案及出资人权益调整方案。法院裁定批准后，公司将进入执行阶段，若执行完毕，利于优化资产负 债结构等，但公司股票已被实施退市及其他风险警示，后续仍存重整失败、股价除权调整等风险。 ...

债务清偿方面，职工债权与税款债权将在重整计划获批后3个月内现金全额清偿；有财产担保债权在担 保财产价值范围内优先现金清偿；普通债权则分档处理，300万元以下部分获现金与股票组合清偿，300 万元以上部分以股票加信托受益权份额抵偿。 同时，公司将通过设立服务信托剥离低效资产，聚焦医美与生物基纤维主业。重整完成后，产业投资人 九州通将发挥医药大健康领域资源优势，助力奥园美谷优化治理、拓展产业链，公司拟通过精细化管 理、资产并购等提升盈利能力。 南方财经12月18日电，*ST美谷(000615.SZ)12月18日公布重整计划，旨在化解债务危机并避免退市风 险，该计划由襄阳市中级人民法院裁定批准。 奥园美谷近年受化纤板块亏损、控股股东债务危机等影响，陷入流动性困境，2025年4月起被实施退市 风险警示。此次重整以7.63亿股总股本为基数，按每10股转增13.43股的比例，共计转增10.25亿股，转 增后总股本将增至17.87亿股。转增股票中，约7630万股向部分股东分配，其余9.48亿股用于引入重整投 资人和抵偿债务。九州产投、信美通成及6家财务投资人组成的重整投资团，将以15.36亿元认购8.62亿 股，其中1.4 ...

*ST美谷公告称，12月16日晚公司收到襄阳中院送达的《民事裁定书》，法院裁定批准《奥园美谷科技 股份有限公司重整计划》并终止公司重整程序。此前，11月14日法院裁定受理债权人对公司的重整申请 并指定管理人；12月15日，债权人会议和出资人组会议均表决通过相关方案。裁定批准后，公司将进入 重整计划执行阶段，若顺利执行完毕，将改善公司状况，对2025年度财务指标产生重大影响。不过，公 司仍面临破产、终止上市及协议履约等风险。 ...

Core Viewpoint - The article discusses the regulatory actions against Renfu Pharmaceutical and its former controlling shareholder, Dongdai Group, highlighting significant financial misconduct and the subsequent restructuring of the company under new control. Group 1: Regulatory Actions and Violations - Renfu Pharmaceutical was officially designated as ST (Special Treatment) on December 16 due to multiple violations, including significant fund occupation and false financial reporting [1][3] - The Hubei Securities Regulatory Bureau issued a notice detailing four main violations from 2020 to 2022, including a total fund occupation of 12.785 billion yuan, which represented a significant percentage of the company's net assets during those years [5][6] - The total fines imposed on Renfu Pharmaceutical and Dongdai Group amounted to 36.7 million yuan, with individual penalties for responsible parties ranging from 500,000 to 3.9 million yuan [8] Group 2: Financial Misconduct Details - The first violation involved non-operational fund occupation, with Dongdai Group occupying 2.502 billion yuan, 8.179 billion yuan, and 2.104 billion yuan in 2020, 2021, and early 2022, respectively [5] - The second violation related to undisclosed related-party transactions, where Renfu Pharmaceutical purchased assets from a company closely related to Dongdai Group without proper disclosure, totaling 1.645 billion yuan [6] - The third violation included false financial records, where Renfu Pharmaceutical inflated its net profit by 143 million yuan, 72 million yuan, and 91 million yuan in 2020, 2021, and the first half of 2022, respectively [6] - The fourth violation involved the concealment of related-party relationships during a transaction, leading to a lack of timely disclosure [7] Group 3: Corporate Restructuring and New Control - Following the financial misconduct, Renfu Pharmaceutical's control was transferred to China Merchants Group, which invested 11.8 billion yuan to acquire a 23.70% voting stake in the company [9][10] - The restructuring process was initiated due to Dongdai Group's severe debt crisis, which included bankruptcy proceedings initiated by creditors [9] - Significant changes in the board and management of Renfu Pharmaceutical occurred post-restructuring, with new appointments from China Merchants Group [10] Group 4: Financial Performance - For the first three quarters of 2025, Renfu Pharmaceutical reported revenues of 17.883 billion yuan, a decrease of 6.58% year-on-year, while net profit attributable to shareholders increased by 6.22% to 1.689 billion yuan [11]

*ST中装公告称，2025年12月16日，公司第二次债权人会议召开，表决通过《深圳市中装建设集团股份 有限公司重整计划（草案）》。有财产担保债权组、劳务债权组、普通债权组均表决通过该草案。不 过，《重整计划（草案）》尚未获深圳中院裁定批准，存在不确定性。公司股票已被实施退市风险警 示，若重整失败被宣告破产，股票将面临终止上市风险。此外，公司股票还存在其他风险警示。 ...

*ST张股公告，公司及全资子公司张家界大庸古城发展有限公司的重整计划已获湖南省张家界市中级人 民法院裁定批准，并终止重整程序。公司将进入重整计划执行阶段，若顺利执行，将改善资产负债结构 及经营状况，提升持续经营和盈利能力，对2025年度财务指标产生积极影响。 ...